Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

Overview of attention for article published in Frontiers in oncology, May 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 3 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,550 followers.

RT @FrontOncology: New research: Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure: Background…

31 May 2021

Reply Repost Favourite

New research: Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure: Background Nivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after… https://t.co/9tFH0

31 May 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.